April 16 (UPI) -- Drugmaker Eli Lilly said Friday it's asked federal regulators to revoke emergency use authorization for lone use of its COVID-19 antibody bamlanivimab, as it develops a combination therapy with the drug it says is more effective.
Eli Lilly made the request with the Food and Drug Administration due to coronavirus variants that may be resistant to bamlanivimab when it's used alone.